» Articles » PMID: 23264940

Simultaneous Determination of Atorvastatin and Aspirin in Human Plasma by LC-MS/MS: Its Pharmacokinetic Application

Overview
Journal Sci Pharm
Publisher MDPI
Specialty Pharmacology
Date 2012 Dec 25
PMID 23264940
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

A simple, rapid, and sensitive liquid chromatography tandem mass spectro-metric (LC-MS/MS) assay method has been developed and fully validated for the simultaneous quantification of atorvastatin and aspirin in human plasma using a polarity switch. Proguanil and furosemide were used as the internal standards for the quantification of atorvastatin and aspirin, respectively. The analytes were extracted from human plasma by the liquid-liquid extraction technique using methyl tert-butyl ether. The reconstituted samples were chromatographed on a Zorbax XDB Phenyl column by using a mixture of 0.2% acetic acid buffer, methanol, and acetonitrile (20:16:64, v/v) as the mobile phase at a flow rate of 0.8 mL/min. Prior to detection, atorvastatin and aspirin were ionized using an ESI source in the multiple reaction monitoring (MRM) mode. The ions were monitored at the positive m/z 559.2→440.0 transition for atorvastatin and the negative m/z 179.0→136.6 transition for aspirin. The calibration curve obtained was linear (r(2) ≥ 0.99) over the concentration range of 0.20-151 ng/mL for atorvastatin and 15.0-3000 ng/mL for aspirin. The method validation was performed as per FDA guidelines and the results met the acceptance criteria. A run time of 3.0 min for each sample made it possible to analyze more than 300 human plasma samples per day. The proposed method was found to be applicable to clinical studies.

Citing Articles

Based on Multi-Activity Integrated Strategy to Screening, Characterization and Quantification of Bioactive Compounds from Red Wine.

Gao Y, Yu X, Wang B, Yin G, Wang J, Wang T Molecules. 2021; 26(21).

PMID: 34771156 PMC: 8587790. DOI: 10.3390/molecules26216750.


Depot injectable atorvastatin biodegradable in situ gel: development, optimization, in vitro, and in vivo evaluation.

Ahmed T, Alharby Y, El-Helw A, Hosny K, El-Say K Drug Des Devel Ther. 2016; 10:405-15.

PMID: 26855565 PMC: 4725642. DOI: 10.2147/DDDT.S98078.


Aspirin inhibits cell viability and mTOR downstream signaling in gastroenteropancreatic and bronchopulmonary neuroendocrine tumor cells.

Spampatti M, Vlotides G, Spottl G, Maurer J, Goke B, Auernhammer C World J Gastroenterol. 2014; 20(29):10038-49.

PMID: 25110431 PMC: 4123333. DOI: 10.3748/wjg.v20.i29.10038.

References
1.
Kannel W . Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens. 2000; 13(1 Pt 2):3S-10S. DOI: 10.1016/s0895-7061(99)00252-6. View

2.
Ghosh C, Jain I, Gaur S, Patel N, Upadhyay A, Chakraborty B . Simultaneous estimation of atorvastatin and its two metabolites from human plasma by ESI-LC-MS/MS. Drug Test Anal. 2011; 3(6):352-62. DOI: 10.1002/dta.228. View

3.
Jain K, Kathiravan M, Somani R, Shishoo C . The biology and chemistry of hyperlipidemia. Bioorg Med Chem. 2007; 15(14):4674-99. DOI: 10.1016/j.bmc.2007.04.031. View

4.
Davidson M, GOLDSTEIN R, Davignon J, Isaacsohn J, Weiss S, Keilson L . Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA. 1996; 275(2):128-33. View

5.
Borek-Dohalsky V, Huclova J, Barrett B, Nemec B, Ulc I, Jelinek I . Validated HPLC-MS-MS method for simultaneous determination of atorvastatin and 2-hydroxyatorvastatin in human plasma-pharmacokinetic study. Anal Bioanal Chem. 2006; 386(2):275-85. DOI: 10.1007/s00216-006-0655-3. View